ResMed Inc. (RMD) Earnings Call Transcripts

ResMed Inc.'s Latest Earnings Call - Q4 FY2026

In Q4 FY2026, ResMed Inc. reported strong financial results with headline revenue of $1.5 billion, reflecting a 9% increase year-over-year, and a non-GAAP EPS of $2.95, up 16%. The company also achieved a full-year revenue growth of 10% and a significant free cash flow of over $1.6 billion. For FY2027, management provided guidance for revenue growth of 5% to 7% and non-GAAP EPS in the range of $12.00 to $12.25, indicating a positive outlook despite challenges from product recalls and inflationary pressures.

Reported metrics

Guidance from management

For FY2027, ResMed expects revenue growth of 5% to 7% and non-GAAP EPS in the range of $12.00 to $12.25, reflecting a commitment to growth despite challenges from the Astral recall.

What management said

I'll just close with this, that, look, ResMed's growth is based on volume. And so we're going to have very modest price increases we're going to work with customers on. But what we are laser-focused on is driving volume, volume of patients into the funnel, re-PAP, resupply, ongoing software sales. So that's our answer to that question. Thank you, Steve, for that question.

Yes. Look, it's a great question. And thank you for your comment there. It's the first time we provided revenue and EPS guidance in the history of ResMed being a public company. But I think, as you said, with the moving pieces, we bought Noctrix, we're integrating VirtuOx. We're selling off MatrixCare. We're not selling Astral for fiscal '27. There's so many moving pieces that we thought it's the right thing to do to...

What analysts pressed on

Analysts expressed concerns regarding the impact of the Astral recall on revenue and earnings, with specific focus on the $75 million headwind expected in FY2027. There were also questions about the sustainability of gross margins amidst inflationary pressures and the pace of innovation in product development.

Main topics on the call

• Revenue Growth — ResMed achieved a 9% increase in Q4 revenue, with a full-year growth of 10%. Management highlighted that 'the core markets remain largely underpenetrated', indicating potential for future growth.
• Product Recalls Impact — The ongoing recall of the Astral devices is expected to create a $75 million revenue headwind in FY2027. Management stated, 'we won't be selling any new product throughout all of fiscal year 2027' due to this issue.
• Innovation and R&D Investment — ResMed is increasing R&D spending by 22% in Q4 to drive innovation in devices and AI solutions. The management emphasized, 'ResMed is an innovation machine' as they continue to enhance patient experience.
• Shareholder Returns — The company plans to return over $1.85 billion to shareholders in FY2027, which includes a 10% increase in quarterly dividends to $0.66 per share. This reflects a commitment to maximizing shareholder value.

Read the full ResMed Inc. transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 71 ResMed Inc. earnings call transcripts on record, spanning January 13, 2020 to August 6, 2026. Based on this history, ResMed Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

RMD

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

71

First call

January 13, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly